Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 19/20 | 1.00 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | HRH2 | P25021 | 1/20 | 0.65 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.65 |
| ▸ | HTR2A | P28223 | 1/20 | 0.65 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.65 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.65 |
| ▸ | HTR2B | P41595 | 1/20 | 0.65 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.65 |
| ▸ | TLR8 | Q9NR97 | 8/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29508382 | 1.00 | TLR7 (1.00) | TLR7NUDT1LMNAPOLBHRH2 | |
| SCHEMBL8522286 | 0.93 | TLR7 (0.87) | TLR7NUDT1LMNAPOLBHRH2 | |
| SCHEMBL6710596 | 0.88 | TLR7 (0.79) | TLR7NUDT1LMNAPOLBHRH2 | |
| SCHEMBL5617088 | 0.85 | TLR7 (0.74) | TLR7NUDT1LMNAPOLBHRH2 | |
| SCHEMBL1895460 | 0.85 | TLR7 (0.73) | TLR7NUDT1LMNAPOLBHRH2 | |
| SCHEMBL4144585 | 0.83 | TLR7 (0.71) | TLR7NUDT1LMNAPOLBHRH2 | |
| SCHEMBL4531190 | 0.83 | TLR7 (0.71) | TLR7NUDT1LMNAPOLBHRH2 | |
| SCHEMBL4531160 | 0.83 | TLR7 (0.71) | TLR7NUDT1LMNAPOLBHRH2 | |
| SCHEMBL1486435 | 0.83 | TLR7 (0.70) | TLR7NUDT1LMNAPOLBHRH2 | |
| SCHEMBL5617005 | 0.83 | TLR7 (0.70) | TLR7NUDT1LMNAPOLBHRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 399 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110002953-A1 | USE OF IMMIDAZOQUINOLINAMINES AS ADJUVANTS IN DNA VACCINATION | THOMSEN LINDY LOUISE | 2011-01-06 | — | — | US | claimed |
| US-20090143724-A1 | Microprojection Array Immunization Patch and Method | ALZA CORPORATION (US) | 2009-06-04 | — | — | US | claimed |
| EP-1318835-B1 | USE OF IMIDAZOQUINOLINAMINES AS ADJUVANTS IN DNA VACCINATION | GLAXO GROUP LTD (GB) | 2008-07-16 | — | — | EP | claimed |
| US-20080145375-A1 | Adjuvant mixture comprising toll like receptor agonist and nucleotide sequences coding colony stimulating factor for use in treatment and prevention of cancer, allergies and autoimmune diseases | GLAXO GROUP LIMITED (GB) | 2008-06-19 | — | — | US | claimed |
| US-20080119508-A1 | Multi-Route Administration Of Immune Response Modifier Compounds | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2008-05-22 | — | — | US | claimed |
| US-20070248614-A1 | Vaccination | GLAXO GROUP LIMITED | 2007-10-25 | — | — | US | claimed |
| EP-1658035-A4 | DELIVERY OF IMMUNE RESPONSE MODIFIER COMPOUNDS | 3M INNOVATIVE PROPERTIES CO (US) | 2007-08-22 | — | — | EP | claimed |
| US-20060195067-A1 | Delivery of immune response modifier compounds | 3M INNOVATIVE PROPERTIES COMPANY | 2006-08-31 | — | — | US | claimed |
| EP-1682175-A2 | IMPROVEMENTS IN VACCINATION | GLAXO GROUP LIMITED (GB) | 2006-07-26 | — | — | EP | claimed |
| EP-1658035-A2 | DELIVERY OF IMMUNE RESPONSE MODIFIER COMPOUNDS | 3M Innovative Properties Company (US) | 2006-05-24 | — | — | EP | claimed |
| US-20040076633-A1 | Use of immidazoquinolinamines as adjuvants in dna vaccination | GLAXO GROUP LIMITED (GB) | 2004-04-22 | — | — | US | claimed |
| EP-1383571-A2 | MICROPROJECTION ARRAY IMMUNIZATION PATCH AND METHOD | Alza Corporation (US) | 2004-01-28 | — | — | EP | claimed |
| US-20020193729-A1 | Microprojection array immunization patch and method | ALZA CORPORATION | 2002-12-19 | — | — | US | claimed |
| WO-2002085446-A2 | MICROPROJECTION ARRAY IMMUNIZATION PATCH AND METHOD | ALZA CORPORATION (US) | 2002-10-31 | — | — | WO | claimed |
| US-6083505-A | IMMUNOGEN/VACCINE ADJUVANT COMPOSITION CONTAINING AN IMMUNOGEN IN AN AMOUNT EFFECTIVE TO STIMULATE AN IMMUNE RESPONSE AND AS A VACCINE ADJUVANT A 1H-IMIDAZO(4,5-C)QUINOLIN-4-AMINE IN AN AMOUNT EFFECTIVE TO INCREASE THE IMMUNE RESPONSE TO THE | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2000-07-04 | — | — | US | claimed |
| EP-0636031-B1 | VACCINE ADJUVANT | MINNESOTA MINING & MFG (US) | 1996-09-04 | — | — | EP | claimed |
| EP-0636031-A1 | VACCINE ADJUVANT. | MINNESOTA MINING & MFG (US) | 1995-02-01 | — | — | EP | claimed |
| WO-1993020847-A1 | VACCINE ADJUVANT | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1993-10-28 | — | — | WO | claimed |
| EP-0394026-B1 | Formulation containing an imidazo[4,5-c]quinolin derivative | RIKER LABORATORIES, INC. (US) | 1993-09-29 | — | — | EP | claimed |
| EP-0394026-A1 | Formulation containing an imidazo[4,5-c]quinolin derivative | RIKER LABORATORIES, INC. (US) | 1990-10-24 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080145375-A1 | Adjuvant mixture comprising toll like receptor agonist and nucleotide sequences coding colony stimulating factor for use in treatment and prevention of cancer, allergies and autoimmune diseases | TLR9, TLR3, MYD88 | TLR7 7/4885NUDT1 939/4885LMNA 4158/4885 |
| US-20040076633-A1 | Use of immidazoquinolinamines as adjuvants in dna vaccination | LY96, TLR9, LIG4 | TLR7 5/4885NUDT1 601/4885LMNA 1303/4885 |
| US-20110002953-A1 | USE OF IMMIDAZOQUINOLINAMINES AS ADJUVANTS IN DNA VACCINATION | LY96, STING1, TLR9 | TLR7 4/4885NUDT1 432/4885LMNA 1200/4885 |
| US-20080119508-A1 | Multi-Route Administration Of Immune Response Modifier Compounds | IFNG, HLA-DRB1, IL2 | TLR7 60/4885NUDT1 3141/4885LMNA 4841/4885 |
| US-20070248614-A1 | Vaccination | TLR7, TLR9, TLR3 | TLR7 1/4885NUDT1 435/4885LMNA 1486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.